NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease)..
Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection
ZyVersa Therapeutics CEO, Stephen C Glover, Featured on Benzinga All Access streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.